ViCentra, a company focused on its automated insulin delivery system, has announced the appointment of Tom Arnold as chief executive officer.

Eleva, a clinical-stage biopharmaceutical company, has announced the appointment of Martin Bauer as its new chief medical officer.

Novo Nordisk has announced the appointment of Sebnem Avsar Tuna as general manager for its UK affiliate.

Glox Therapeutics, a precision medicine company spun out from the Universities of Oxford and Glasgow, has announced the appointments of Michael Murray (pictured) as chair of the board and Nel Moore as scientific advisory board member.

Sapio Sciences, a provider of lab informatics solutions, has announced the appointment of Mike Hampton as chief commercial officer and unveiled its new scientific office.

Nuclera has announced the appointment of Seth Benson as its new chief financial officer, following the strengthening of its leadership team with three key appointments at the end of last year.

The International Drug Development Institute (IDDI) has announced changes to its executive leadership team to strengthen the company’s leadership and operational capabilities.

David Loose has been appointed as chief executive officer of Essex Management, part of contract research organisation Emmes Group.

Vect-Horus, a private biotechnology company specialising in molecular development, has announced the appointment of Jérôme Berger to its board of directors.

PrecisionLife has appointed seasoned executive Bill Keating as chief commercial officer of Diagnostics and Healthcare to drive commercial strategy for precision medicine.

Novel obesity treatment-focused biopharmaceutical company Antag Therapeutics has announced the appointment of Joerg Moeller MD PhD as chief executive officer.

Exevir Bio, a biotech company focused on developing heavy chain-only antibodies to target highly conserved epitopes for broad-spectrum protection against infectious diseases, has announced the appointment of Michael Garrett as its new CEO.